Daniel Simon

NetSuite Amazon SES Sendgrid Mimecast Outlook MailChimp SPF Microsoft Office 365 WP Engine OneTrust Remote

synthetic lethality & precision medicine biotechnology: pharmaceutical preparations health care biotechnology research precision medicine oncology targeted therapeutics molecular diagnostics synthetic lethality clinical-stage biomarker discovery cancer drug development early discovery clinical trials therapeutic window gnaq mutations gna11 mutations mat2a inhibition parg inhibition homologous recombination deficiency translational biology tumor biology crispr gene editing tumor profiling small molecule inhibitors protein kinase c biomarker selection expanded access solid tumors therapeutic efficacy genetic alterations cell viability tumor microenvironment drug discovery platform first-in-class therapeutics best-in-class therapeutics clinical trial collaboration combinatorial therapies investigational drugs pharmacological inhibition fda approval oncogenic pathways tumor suppressor genes vulnerability targeting therapeutic candidates advanced solid tumors molecular biology patient stratification collaborative research biopharma partnerships regulatory compliance therapeutic strategies cancer treatment personalized therapy adult cancer patients genetic vulnerabilities drug discovery clinical-stage programs biomarker-driven development innovative therapeutics healthcare providers pharmaceutical collaborations genetic profiling advanced cancer therapies unmet medical needs ai-driven drug discovery oncology research patient-centered approach therapeutic pipeline cancer biomarkers precision oncology therapeutic innovation cancer patient demographics biotechnology pharmaceuticals global healthcare access cancer research partnerships health wellness & fitness hospital & health care medical